Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Insulin, antibodies for use in vaccines and cancer medicines, enzymes for the food, cosmetics, and detergent industries: many such substances can already be produced on a large scale using biotechnology. Currently, demand for biomolecules is often still met by making use of living cells or organisms. This involves researchers adding the gene that codes for the target protein to bacteria, yeasts, or cultures of animal or plant cells. These modified organisms are then cultivated en masse in bioreactors before the protein is finally isolated and purified. There is no doubt that the technology is very effective, but it does have disadvantages, as many of the steps in the process are costly and time-consuming. What's more, the bacteria and other cells themselves consume part of the resources to stay alive - which reduces the efficiency of the protein synthesis process. Project leader Prof. Frank Fabian Bier from the Fraunhofer Institute for Biomedical Engineering IBMT in Potsdam explains the biggest disadvantage of cell-based techniques: "Many proteins cannot be produced in cells - or else the results are very poor. Take membrane proteins, for instance, which play a major role in pharmacological research. Or proteins that poison a cell when present in high concentrations - making them potentially very useful for treating cancer."
Producing proteins without cells
Cell-free techniques do not suffer from these problems, because instead of employing intact, living cells they take only those elements of a cell needed for protein synthesis. But how does the concept of biomolecules for the production line work? First, Fraunhofer researchers must break down the cells to obtain a mixture - known as a lysate - that contains all the necessary elements for protein synthesis. Alongside enzymes, this also includes biologically active organelles and membrane parts that synthesize the proteins according to their genetic coding. The desired genes can be added straight to the lysate; there is no longer any need for them to be implanted laboriously into the cells' DNA first.
The concept of cell-free protein synthesis has been around for a while. What the joint Fraunhofer research project seeks to do is adapt the technique for industrial production. The idea originated from the German Federal Ministry of Education and Research BMBF's Biotechnology 2020+ strategy process and is receiving 15 million euros in funding; the Fraunhofer-Gesellschaft is investing a further 6 million euros. Much has been achieved since the project was launched two years ago. The first stage was the development of automated cell harvesting and extraction techniques to produce lysates from bacteria, tobacco, and insect cells. A completely automated process supplies these lysates with amino acids and selected genetic material so that the synthesis of specific proteins can get underway.
Two bioreactor concepts
Two reactor concepts are currently undergoing testing for use in industry. One idea consists of small synthesis chambers with a partially permeable membrane through which fresh stores of ingredients for the reaction can be fed to the lysate and harmful metabolites removed. A supply and disposal system of this kind allows protein synthesis to keep going for several days. The other idea is for a microfluidic platform on which the reading of the genes and actual protein synthesis occur in separate places - in much the same way as it does in animals and plants. This system is particularly suited to lysates from animal and plant cells.
The trial reactors are the result of intensive collaboration between biologists, physicists, and mechanical and electronics engineers from the eight participating Fraunhofer Institutes. "Since the launch of the project in March 2011, we've put a tremendous amount of effort into producing suitable lysates, establishing measurement techniques, and putting together components that can control the processes involved," stresses Prof. Bier. He concludes: "There is still a lot of scope to improve cell-free systems, and they show huge potential for making the large-scale production of important biomolecules far more economical and sparing with resources than ever before."
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Pharma Industry / Biotech Industry category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Fraunhofer-Gesellschaft. "Biomolecules for the production line." Medical News Today. MediLexicon, Intl., 25 Oct. 2013. Web.
8 Dec. 2013. <http://www.medicalnewstoday.com/releases/267874>
Fraunhofer-Gesellschaft. (2013, October 25). "Biomolecules for the production line." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/267874.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.